

New pantacyclic tacrines as potent acetylcholinesterase inhibitors

M. Alipour^{1,*}, M. Khoobi², A. Shafiee³, M. Ghandi¹

¹*School of Chemistry, University of Tehran, Tehran, Iran*

²*Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran*

³*Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran*

Background and Aims: Importance of cholinesterase inhibition as a promising strategy for the treatment of Alzheimer, senile dementia, ataxia, and Parkinson's disease has spurred the development of numerous structural classes of compounds. Tacrine, a potent and reversible AChE inhibitor, was the first drug approved in the USA for the palliative treatment of AD; however, it exhibited side effects like hepatotoxicity. Current research is focused on developing new AChE inhibitors with improved activity and reduced adverse side effects of Tacrine.

Methods: In this context, we designed and synthesized new series of pantacyclic derivatives which could be easily prepared by the AlCl₃ promoted Friedländer reaction between the corresponding, known dihydropyrano[c]chromenes and cyclohexanone. Corresponding 2-amino-3-cyano dihydropyrano[c]chromenes were easily prepared with simple treatment of 4-hydroxycoumarin with malononitrile and various benzyl halides.

Results: The anticholinesterase activity of synthesized compounds was measured using colorimetric Ellman's method. A significant AChE inhibitory activity was observed for most of these synthesized compounds.

Conclusions: In this work we've synthesized a new series of pyranocoumarin fused to tacrine as pantacyclic heterocyclic as novel acetylcholinesterase inhibitors. Assuming biological data showed high inhibitory activity against acetyl cholinesterase enzyme with IC₅₀ values within pico and nano molar ranges.

Keywords: Acetylcholinesterase inhibitors; Pyranocoumarin; Tacrine; Ellman's method